KT-413

About Kymera Therapeutics

Kymera Therapeutics is a leader in the targeted protein degradation field, translating its innovative Pegasus™ platform into a robust clinical pipeline. The company has achieved significant validation through positive early clinical data for its lead programs, KT-621 and KT-333, demonstrating proof-of-concept for its oral degraders. Kymera's strategy is to build a fully integrated biopharmaceutical company by advancing its wholly-owned assets while selectively leveraging strategic partnerships to expand its reach and capabilities.

Therapeutic Areas